Panobinostat (LBH589) is a pan-HDAC-inhibitor with high efficacy in several preclinical models of cancer [188], and treatment of panobinostat combined with sorafenib demonstrated higher preclinical efficacy in HCC [189]. The gene discussed is HDAC9; the disease is hepatocellular carcinoma.